Vanda Board Approves 2025 Bonuses and 2026 Compensation
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vanda ( (VNDA) ) just unveiled an announcement.
On February 18, 2026, Vanda’s board compensation committee approved 2025 cash bonuses for its named executive officers, including a bonus of $834,326 for President and CEO Mihael H. Polymeropoulos, following a peer-based compensation review by consultant Willis Towers Watson. Senior executives including the CFO, head of business development, chief marketing officer and general counsel received bonuses in the $272,129–$281,686 range for performance in the year ended December 31, 2025.
The committee also set 2026 base salaries and target bonus percentages, raising the CEO’s salary to $994,625 with an 80% bonus target, while other top executives received base pay of about $576,735–$596,990 with 45% bonus targets. In addition, the committee granted time-based RSUs that vest over four years starting March 1, 2027, and PSUs tied to relative total shareholder return versus the Nasdaq Biotechnology Index over a three-year period ending December 31, 2028, linking potential payouts ranging from 50% to 150% of target to long-term stock performance and executive retention.
The most recent analyst rating on (VNDA) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.
Spark’s Take on VNDA Stock
According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.
The score is held back primarily by weak financial performance—deep 2025 losses, heavy cash burn, and declining equity—despite low leverage. Offsetting factors include a constructive longer-term technical trend and earnings-call positives (2026 growth guidance, strong Fanapt momentum, and Nereus approval), though valuation remains constrained by losses and regulatory/execution risks.
To see Spark’s full report on VNDA stock, click here.
More about Vanda
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies, with its leadership team overseeing functions including finance, business development, marketing and legal operations. The company operates in the Nasdaq-listed biotechnology space, aligning its executive compensation and equity incentives with shareholder returns and sector benchmarks.
Average Trading Volume: 1,759,191
Technical Sentiment Signal: Buy
Current Market Cap: $366.5M
For an in-depth examination of VNDA stock, go to TipRanks’ Overview page.
